SEC Form 4 · accession 0000899243-16-025639

Coherus Oncology, Inc. · CHRS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Technical Officer

Period of report

Jul 21, 2016

Accepted (ET)

Jul 25, 2016 · 4:05 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001512762

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock, $0.0001 par value	Jul 21, 2016	M	3,991	$2.0838	A	3,991	D
Common Stock, $0.0001 par value^F2	Jul 21, 2016	S	3,291	$26.0513	D	700	D
Common Stock, $0.0001 par value^F3	Jul 21, 2016	S	700	$26.4814	D	0	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F4	$2.0838	Jul 21, 2016	M	3,991	D	—	Dec 13, 2022	Common Stock	3,991	88,503	D

F1The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person.
F2The transaction was executed in multiple trades in prices ranging from $25.41 to $26.39, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
F3The transaction was executed in multiple trades in prices ranging from $26.42 to $26.61, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
F4All shares underlying this option are vested and exercisable as of the date hereof.